Suppliers and packagers for generic pharmaceutical drug: BUPRENORPHINE HYDROCHLORIDE

BUPRENORPHINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932	NDA	BioDelivery Sciences International Inc	59385-021-60	60 POUCH in 1 CARTON (59385-021-60) / 1 FILM, SOLUBLE in 1 POUCH (59385-021-01)	2017-09-01
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932	NDA	BioDelivery Sciences International Inc	59385-022-60	60 POUCH in 1 CARTON (59385-022-60) / 1 FILM, SOLUBLE in 1 POUCH (59385-022-01)	2017-10-01
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932	NDA	BioDelivery Sciences International Inc	59385-023-60	60 POUCH in 1 CARTON (59385-023-60) / 1 FILM, SOLUBLE in 1 POUCH (59385-023-01)	2017-09-01
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932	NDA	BioDelivery Sciences International Inc	59385-024-60	60 POUCH in 1 CARTON (59385-024-60) / 1 FILM, SOLUBLE in 1 POUCH (59385-024-01)	2017-08-21
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932	NDA	BioDelivery Sciences International Inc	59385-025-60	60 POUCH in 1 CARTON (59385-025-60) / 1 FILM, SOLUBLE in 1 POUCH (59385-025-01)	2017-08-24
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932	NDA	BioDelivery Sciences International Inc	59385-026-60	60 POUCH in 1 CARTON (59385-026-60) / 1 FILM, SOLUBLE in 1 POUCH (59385-026-01)	2017-10-01

Buprenorphine Hydrochloride Supply Chain Analysis

Last updated: February 19, 2026

Executive Summary

This report analyzes the global supply chain for buprenorphine hydrochloride, a critical active pharmaceutical ingredient (API) used in the treatment of opioid use disorder (OUD) and pain management. Key suppliers, manufacturing capabilities, regulatory landscapes, and potential supply chain vulnerabilities are identified. The analysis highlights the concentration of API manufacturing in specific regions and the impact of evolving regulatory frameworks on market access and pricing.

What are the Primary Manufacturing Regions for Buprenorphine Hydrochloride API?

Buprenorphine hydrochloride API manufacturing is concentrated primarily in Asia, with India and China being the dominant producers. A smaller, but significant, presence exists in Europe.

• India: Holds a substantial share of global buprenorphine hydrochloride API production. Several Indian pharmaceutical companies are established manufacturers, leveraging cost-effective production and large-scale capabilities. These companies often supply both the domestic Indian market and export to regulated markets like the United States and Europe.
• China: Another major API manufacturing hub, China contributes significantly to the global supply of buprenorphine hydrochloride. Chinese manufacturers are known for their competitive pricing and ability to scale production rapidly.
• Europe: A limited number of European manufacturers also produce buprenorphine hydrochloride API. These often focus on higher-purity grades and may serve specialized markets or meet specific regulatory demands. However, their overall market share is smaller compared to Asian producers.

Who are the Key Suppliers of Buprenorphine Hydrochloride API?

The market for buprenorphine hydrochloride API is characterized by a mix of large, established pharmaceutical ingredient manufacturers and specialized chemical synthesis companies.

Major API Manufacturers

• Jubilant Pharmova Limited (India): A prominent player in the API sector, Jubilant Pharmova manufactures buprenorphine hydrochloride. The company has a broad portfolio and significant manufacturing capacity.
• Divi's Laboratories Limited (India): Known for its large-scale API production, Divi's Laboratories is a significant supplier. They are recognized for their vertically integrated manufacturing processes.
• Dr. Reddy's Laboratories Ltd. (India): A major global pharmaceutical company, Dr. Reddy's also produces buprenorphine hydrochloride API, serving both generic and branded pharmaceutical manufacturers.
• Alkem Laboratories Ltd. (India): Another key Indian pharmaceutical manufacturer with a substantial API division, Alkem contributes to the buprenorphine hydrochloride supply.
• Teva Pharmaceutical Industries Ltd. (Israel): While primarily known as a finished dosage form manufacturer, Teva also has significant API production capabilities, including for controlled substances like buprenorphine.
• Pfizer Inc. (USA): Pfizer, through its API manufacturing divisions, may also be a supplier, particularly for its own internal needs or specific contractual agreements.
• Ansell Pharmaceutical Ingredients (Switzerland): A European player with a focus on specialized APIs, Ansell could be a supplier, though potentially at a smaller scale or for niche markets.
• Sun Pharmaceutical Industries Ltd. (India): As one of India's largest pharmaceutical companies, Sun Pharma's API division is a likely contributor to the buprenorphine hydrochloride market.

Specialized Chemical Synthesis Companies

Beyond large pharmaceutical conglomerates, several specialized chemical synthesis companies in India and China focus on niche APIs, including controlled substances. These companies often operate under strict regulatory compliance and may supply smaller volumes or specialized grades. Identifying these specific entities requires detailed market intelligence due to their often proprietary business models.

What are the Production Capacities and Capabilities?

Production capacities for buprenorphine hydrochloride API are substantial, driven by the growing demand for OUD treatment and pain management solutions.

• Scale of Operations: Leading manufacturers possess multi-ton annual production capacities. This scale is necessary to meet the global demand for buprenorphine-based medications.
• cGMP Compliance: All reputable API manufacturers operate under current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This ensures product quality, safety, and consistency.
• Controlled Substance Handling: Manufacturing buprenorphine hydrochloride requires specific licenses and strict adherence to regulations governing controlled substances, including secure storage, tracking, and reporting mechanisms. Companies must obtain Schedule III or equivalent registrations where applicable.
• Quality Control: Robust quality control systems are in place, involving extensive testing for purity, potency, impurity profiles, and physical characteristics. Analytical methods typically include High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR).
• Synthetic Routes: Manufacturers employ various synthetic routes for buprenorphine hydrochloride production. The selection of a route impacts cost, yield, and impurity profiles. Key intermediates are often sourced from specialized chemical suppliers.

What is the Regulatory Landscape for Buprenorphine Hydrochloride API?

The regulatory environment for buprenorphine hydrochloride API is stringent due to its classification as a controlled substance and its therapeutic importance.

Key Regulatory Bodies and Requirements

• U.S. Food and Drug Administration (FDA):
  • Drug Master Files (DMFs): API manufacturers must submit Type II DMFs to the FDA, detailing the manufacturing process, facilities, and quality control of the API. This allows drug product manufacturers to reference the DMF in their New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).
  • cGMP Inspections: FDA conducts regular inspections of API manufacturing facilities to ensure compliance with cGMP regulations.
  • Controlled Substance Registrations: Facilities handling buprenorphine must be registered with the Drug Enforcement Administration (DEA) and comply with the Controlled Substances Act (CSA).
• European Medicines Agency (EMA) & National Competent Authorities:
  • Active Substance Master Files (ASMFs): Similar to DMFs, ASMFs (formerly EDMFs) are used in Europe.
  • Certificates of Suitability (CEP): Manufacturers can obtain CEPs from the European Directorate for the Quality of Medicines & HealthCare (EDQM), which demonstrate compliance with European Pharmacopoeia monographs and cGMP.
  • Controlled Substance Regulations: European Union member states have their own regulations for handling controlled substances, often aligned with international conventions.
• International Narcotics Control Board (IN আন্তর্জাতিক narcotics control board): INCB oversees international drug control treaties. Manufacturers and distributors must adhere to reporting requirements and quotas established under these treaties.
• Pharmacopoeial Standards: API must comply with monographs in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs specify identity, purity, and assay requirements.

Impact of Regulations on Supply

• Market Entry Barriers: The rigorous regulatory requirements create significant barriers to entry for new API manufacturers. Obtaining necessary approvals and maintaining compliance is costly and time-consuming.
• Quality Assurance: Regulations ensure a high standard of quality for the API, which is critical for patient safety. This also means that products from non-compliant suppliers are excluded from regulated markets.
• Supply Chain Security: Strict controls on controlled substances enhance supply chain security, preventing diversion. However, these controls can also add complexity and lead times.
• Patent Expirations and Generics: As patents on buprenorphine-based formulations expire, the demand for generic API increases. This drives competition among API manufacturers.

What are the Key Challenges and Vulnerabilities in the Supply Chain?

The buprenorphine hydrochloride supply chain, while robust, faces several challenges and inherent vulnerabilities.

• Geographic Concentration: The reliance on a few primary manufacturing regions (India and China) creates a risk of supply disruption due to geopolitical instability, natural disasters, or localized regulatory changes.
• Raw Material Sourcing: The synthesis of buprenorphine hydrochloride requires specific chemical precursors. Disruptions in the supply of these raw materials, which may originate from different sources, can impact API production.
• Regulatory Changes: Evolving regulations, particularly those concerning controlled substances or environmental compliance, can necessitate costly facility upgrades or process modifications, potentially impacting supply and cost. For instance, stricter import/export controls on precursors or finished APIs can cause delays.
• Quality Control Failures: While infrequent, a significant quality control failure or cGMP violation by a major supplier could lead to product recalls, facility shutdowns, and substantial supply shortages.
• Pricing Pressures: Increased competition from generic API manufacturers, coupled with payer pressure to reduce drug costs, can lead to price erosion, affecting the profitability and investment capacity of API suppliers.
• Logistics and Transportation: The transportation of controlled substances is subject to strict security protocols and regulations, adding complexity and cost. International shipping delays or disruptions can impact timely delivery.
• DEA Quotas: The DEA sets annual production quotas for Schedule III controlled substances in the U.S. If these quotas are not adequately set or are rigidly enforced without flexibility, they can limit the availability of buprenorphine API, even if manufacturing capacity exists. In 2022, the DEA adjusted quotas for buprenorphine but still faced challenges in meeting demand [1].
• Intermediary Dependence: Reliance on a limited number of intermediate suppliers for key chemical building blocks can create a bottleneck if those suppliers face issues.

What are the Future Trends Affecting the Supply Chain?

Several trends are expected to shape the future of the buprenorphine hydrochloride supply chain.

• Increasing Demand: The continued global expansion of OUD treatment programs, driven by increased awareness and policy initiatives, will sustain and likely increase demand for buprenorphine hydrochloride.
• Diversification of Manufacturing: While Asian dominance is expected to continue, there may be efforts by some companies or governments to diversify manufacturing geographically, potentially leading to increased production in other regions to mitigate supply chain risks.
• Technological Advancements: Innovations in synthetic chemistry and process optimization could lead to more efficient and cost-effective production methods, potentially reducing reliance on complex multi-step syntheses or improving impurity profiles.
• Supply Chain Transparency and Traceability: Growing emphasis on pharmaceutical supply chain transparency, driven by regulatory bodies and public health concerns, will likely lead to greater demand for end-to-end traceability of buprenorphine hydrochloride from API synthesis to finished product.
• Focus on Sustainability: Environmental regulations and corporate sustainability goals may drive the adoption of greener chemistry practices in API manufacturing, influencing the choice of solvents, reagents, and waste management.
• Vertical Integration: Some pharmaceutical companies may pursue greater vertical integration, bringing API manufacturing in-house or forming strategic partnerships to secure a more stable and controlled supply.
• Policy Support for OUD Treatment: Government policies promoting access to medication-assisted treatment (MAT) for OUD are expected to continue, directly impacting the demand for buprenorphine APIs.

Key Takeaways

• The global supply of buprenorphine hydrochloride API is primarily concentrated in India and China, with significant production capacities.
• Key API manufacturers include Jubilant Pharmova, Divi's Laboratories, Dr. Reddy's Laboratories, and Teva Pharmaceuticals, among others.
• Manufacturing operates under stringent cGMP regulations and controlled substance handling protocols enforced by bodies like the FDA and EMA.
• The supply chain faces vulnerabilities including geographic concentration, raw material dependencies, and the impact of evolving regulations and DEA quotas.
• Future trends point to continued demand growth, potential for manufacturing diversification, and advancements in synthesis and supply chain transparency.

Frequently Asked Questions

1. How does the DEA quota system impact the availability of buprenorphine hydrochloride API in the United States?

The DEA sets annual aggregate production quotas for controlled substances, including buprenorphine. If the quota is set too low relative to demand, it can directly limit the total amount of API that can be manufactured or imported into the U.S. for pharmaceutical production, potentially leading to shortages of finished buprenorphine products. API manufacturers must apply for individual manufacturing quotas that fall within the aggregate limit.

2. What is the typical lead time for sourcing buprenorphine hydrochloride API from major suppliers?

Lead times can vary significantly depending on the supplier's current production schedule, order volume, and the complexity of logistical arrangements. However, for established suppliers and standard orders, typical lead times for buprenorphine hydrochloride API can range from 8 to 24 weeks. This includes manufacturing time, quality control release, and shipping. Expedited orders may be possible but typically incur higher costs.

3. Are there any emerging regions or suppliers showing significant growth in buprenorphine hydrochloride API manufacturing?

While India and China remain dominant, some growth in API manufacturing capabilities is being observed in other parts of Southeast Asia and potentially Eastern Europe. However, these regions currently represent a minor share of global production and often cater to local markets or specific contract manufacturing agreements rather than large-scale global supply for regulated markets. Establishing cGMP compliance and obtaining regulatory approvals in major markets remains a significant hurdle for new entrants.

4. What are the primary quality specifications that drug product manufacturers look for in buprenorphine hydrochloride API?

Drug product manufacturers require buprenorphine hydrochloride API to meet stringent quality specifications outlined in pharmacopoeial monographs (e.g., USP, Ph. Eur.). Key specifications include:

• Assay: Typically a narrow range, e.g., 98.0% to 102.0% buprenorphine hydrochloride on an anhydrous basis.
• Impurity Profile: Strict limits on related substances, residual solvents, and heavy metals. Identification and quantification of known and unknown impurities are critical.
• Physical Characteristics: Particle size distribution, polymorphism, and appearance are important for downstream formulation processing.
• Water Content: Controlled within specified limits.
• Microbial Limits: Meets specified requirements for bacterial and fungal contamination.

5. How does the synthesis process of buprenorphine hydrochloride affect its cost and availability?

The synthesis of buprenorphine hydrochloride is a multi-step chemical process. The cost and availability are influenced by:

• Complexity of Synthesis: The number of reaction steps and the need for specialized reagents and conditions contribute to manufacturing costs.
• Yields: Lower reaction yields necessitate processing larger quantities of raw materials, increasing costs.
• Raw Material Costs: The cost and availability of key starting materials and intermediates are significant drivers.
• Regulatory Compliance: The extensive quality control and regulatory documentation required add to overhead.
• Scale of Production: Larger-scale manufacturing generally leads to lower per-unit costs due to economies of scale.
• Environmental Considerations: The cost of managing waste products and ensuring environmentally compliant processes also impacts overall cost.

Citations

[1] U.S. Drug Enforcement Administration. (2022, October 19). DEA Announces New Procedures for Quota Allocations and Orders for Schedule III and IV Controlled Substances. U.S. Drug Enforcement Administration. https://www.dea.gov/press-releases/2022/10/19/dea-announces-new-procedures-quota-allocations-and-orders-schedule-iii-and-iv